Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart

NCT01438775 is registered in ClinicalTrials.gov with Nymox Corporation as lead sponsor.

NCT NCT01438775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01438775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Lead sponsor
Nymox Corporation
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2011
Completion date
January 31, 2013
Enrollment
192 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia